Betsy Williams
IQVIA (United States)(US)
Publications by Year
Research Areas
Epilepsy research and treatment, Pharmacological Effects and Toxicity Studies, Neuroscience and Neuropharmacology Research, Pharmaceutical studies and practices, Drug Transport and Resistance Mechanisms
Most-Cited Works
- → Randomized Phase III Intergroup Trial of Isotretinoin to Prevent Second Primary Tumors in Stage I Non-Small-Cell Lung Cancer(2001)319 cited
- → Psychiatric and behavioral adverse events in randomized clinical studies of the noncompetitive AMPA receptor antagonist perampanel(2015)133 cited
- → Final safety, tolerability, and seizure outcomes in patients with focal epilepsy treated with adjunctive perampanel for up to 4 years in an open‐label extension of phase III randomized trials: Study 307(2018)97 cited
- → Long‐term asthma control with oral montelukast and inhaled beclomethasone for adults and children 6 years and older(2001)89 cited
- → Efficacy and safety of perampanel in adolescent patients with drug-resistant partial seizures in three double-blind, placebo-controlled, phase III randomized clinical studies and a combined extension study(2015)77 cited
- → Efficacy and safety of perampanel in the subgroup of elderly patients included in the phase III epilepsy clinical trials(2014)49 cited
- → Long-term effects of adjunctive perampanel on cognition in adolescents with partial seizures(2018)48 cited
- → Phase I clinical, pharmacokinetic, and pharmacodynamic study of the Akt-inhibitor triciribine phosphate monohydrate in patients with advanced hematologic malignancies(2013)45 cited
- → Perampanel in the treatment of partial seizures: Time to onset and duration of most common adverse events from pooled Phase III and extension studies(2015)38 cited
- → Perampanel efficacy and safety by gender: Subanalysis of phase III randomized clinical studies in subjects with partial seizures(2015)36 cited